Physician profile
Min Win
NPI 1316079619
$2,986.66
in general payments reported to CMS, 2019-2025
23 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $250 · 2021: $300 · 2022: $508 · 2023: $493 · 2024: $200 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $750.06 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $627.28 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $281.00 | 2019-2022 | |
| Boston Scientific Corporation | $236.61 | 2019-2025 | General - Biliary Devices, Exalt Model D, Axios |
| Gilead Sciences, INC. | $178.15 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $132.69 | 2019-2025 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.46 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $80.81 | 2019-2020 | |
| Qol Medical, LLC | $79.82 | 2019-2024 | Sucraid, Sucraid |
| Shionogi INC | $74.81 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $55.48 | 2019-2023 | Ocaliva |
| Celltrion USA INC. | $50.24 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $47.88 | 2024-2025 | Voquezna |
| Pfizer INC. | $46.26 | 2020-2025 | |
| Daiichi Sankyo INC. | $35.84 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $32.46 | 2021-2022 | |
| Alfasigma USA, INC. | $31.88 | 2021 | |
| Celgene Corporation | $31.41 | 2022 | |
| Allergan, INC. | $25.10 | 2019-2020 | |
| Ardelyx, INC. | $21.43 | 2023 | Ibsrela |
| Novo Nordisk INC | $20.89 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $15.95 | 2023 | Sutab |
| Concordia Pharmaceuticals INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.